Pharmaceutical Industry Today
Oral Antidiabetic (OAD) Treatment 2018 Global Market Key Players - Pfizer, Eli Lilly, Merck, Sanofi, AstraZeneca, Glenmark, Novartis......
Oral Antidiabetic (OAD) Treatment Market 2018
Wiseguyreports.Com Adds “Oral Antidiabetic (OAD) Treatment – Global Market Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database.
Description:
This report focuses on the global Oral Antidiabetic (OAD) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oral Antidiabetic (OAD) Treatment development in United States, Europe and China.
Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. Various treatment method are present in the market injection, oral and others. The mostly used method of treatment or managing the diabetes is the oral.
North America has the 44.3 million population with diabetes in 2015 according to the IDF, same as Europe have 59.8 million in 2015 according to IDF and Asia Pacific has 60% diabetic population as compared with world according to Asian Diabetes Prevention Initiative.
In 2017, the global Oral Antidiabetic (OAD) Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.
The key players covered in this study
Pfizer
Eli Lilly
Merck
Sanofi
AstraZeneca
Glenmark
Novartis
Boehringer Ingelheim
Novo Nordisk
Mannkind
Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3407705-global-oral-antidiabetic-oad-treatment-market-size-status-and-forecast-2018-2025
Market segment by Type, the product can be split into
Sulphonylureas
Biguanides
Intestinal α-Glucosidase Inhibitors
Others
Market segment by Application, split into
Hospital
Clinics
Diabetics Treatment Centres
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
Enquiry before Buying @ https://www.wiseguyreports.com/enquiry/3407705-global-oral-antidiabetic-oad-treatment-market-size-status-and-forecast-2018-2025
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Content:
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Oral Antidiabetic (OAD) Treatment Market Size Growth Rate by Type (2013-2025)
1.4.2 Sulphonylureas
1.4.3 Biguanides
1.4.4 Intestinal α-Glucosidase Inhibitors
1.4.5 Others
1.5 Market by Application
1.5.1 Global Oral Antidiabetic (OAD) Treatment Market Share by Application (2013-2025)
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Diabetics Treatment Centres
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Oral Antidiabetic (OAD) Treatment Market Size
2.2 Oral Antidiabetic (OAD) Treatment Growth Trends by Regions
2.2.1 Oral Antidiabetic (OAD) Treatment Market Size by Regions (2013-2025)
2.2.2 Oral Antidiabetic (OAD) Treatment Market Share by Regions (2013-2018)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
……..
12 International Players Profiles
12.1 Pfizer
12.1.1 Pfizer Company Details
12.1.2 Company Description and Business Overview
12.1.3 Oral Antidiabetic (OAD) Treatment Introduction
12.1.4 Pfizer Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.1.5 Pfizer Recent Development
12.2 Eli Lilly
12.2.1 Eli Lilly Company Details
12.2.2 Company Description and Business Overview
12.2.3 Oral Antidiabetic (OAD) Treatment Introduction
12.2.4 Eli Lilly Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.2.5 Eli Lilly Recent Development
12.3 Merck
12.3.1 Merck Company Details
12.3.2 Company Description and Business Overview
12.3.3 Oral Antidiabetic (OAD) Treatment Introduction
12.3.4 Merck Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.3.5 Merck Recent Development
12.4 Sanofi
12.4.1 Sanofi Company Details
12.4.2 Company Description and Business Overview
12.4.3 Oral Antidiabetic (OAD) Treatment Introduction
12.4.4 Sanofi Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.4.5 Sanofi Recent Development
12.5 AstraZeneca
12.5.1 AstraZeneca Company Details
12.5.2 Company Description and Business Overview
12.5.3 Oral Antidiabetic (OAD) Treatment Introduction
12.5.4 AstraZeneca Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.5.5 AstraZeneca Recent Development
12.6 Glenmark
12.6.1 Glenmark Company Details
12.6.2 Company Description and Business Overview
12.6.3 Oral Antidiabetic (OAD) Treatment Introduction
12.6.4 Glenmark Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.6.5 Glenmark Recent Development
12.7 Novartis
12.7.1 Novartis Company Details
12.7.2 Company Description and Business Overview
12.7.3 Oral Antidiabetic (OAD) Treatment Introduction
12.7.4 Novartis Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.7.5 Novartis Recent Development
12.8 Boehringer Ingelheim
12.8.1 Boehringer Ingelheim Company Details
12.8.2 Company Description and Business Overview
12.8.3 Oral Antidiabetic (OAD) Treatment Introduction
12.8.4 Boehringer Ingelheim Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.8.5 Boehringer Ingelheim Recent Development
12.9 Novo Nordisk
12.9.1 Novo Nordisk Company Details
12.9.2 Company Description and Business Overview
12.9.3 Oral Antidiabetic (OAD) Treatment Introduction
12.9.4 Novo Nordisk Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.9.5 Novo Nordisk Recent Development
12.10 Mannkind
12.10.1 Mannkind Company Details
12.10.2 Company Description and Business Overview
12.10.3 Oral Antidiabetic (OAD) Treatment Introduction
12.10.4 Mannkind Revenue in Oral Antidiabetic (OAD) Treatment Business (2013-2018)
12.10.5 Mannkind Recent Development
Continued…..
Contact US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Share on Social Media
Other Industry News
Ready to start publishing
Sign Up today!